Ernest Pharmaceuticals

Ernest Pharmaceuticals has engineered a patented
Bacterial Intracellular Delivery vector (BacID) that can produce and deliver biological drugs specifically to solid tumor cells. They have developed two bacterial therapies:
1) EBT-002 with a focus on heterogeneous tumors without biomarkers, such as liver cancer and
2) EBT-305, an immune strategy for ICI-resistant tumors.
Both therapies are in preclinical development, with proof of concept in mice. In addition to their in-house pipeline, they have engineered the BacID platform to easily implement other biological compounds for the development of partnered programs with other drug developers.